The use of bevacizumab in pediatric retinal and choroidal disease: A review

Abstract

The use of intravitreal bevacizumab in pediatric retinal and uveitic disease has become more widespread over the past decade. This article serves to outline the rationale underlying the use of intravitreal bevacizumab, and which disease entities it should be appropriately thought of as a primary or solo therapy, as opposed to an adjuvant one. Also presented is the relevant literature regarding each of these retinopathies.

Keywords

Bevacizumab retinopathy of prematurity Coats’ disease familial exudative vitreoretinopathy sickle cell retinopathy choroidal neovascularization

Get full access to this article

View all access options for this article.

References

Sisk

Berrocal

Albini

et al . Bevacizumab for the treatment of pediatric retinal and choroidal diseases. Ophthalmic Surg Lasers Imaging 2010; 41(6): 582–592.

Henry

Sisk

Tzu

et al . Long-term follow-up of intravitreal bevacizumab for the treatment of pediatric retinal and choroidal diseases. J AAPOS 2015; 19(6): 541–548.

Bou

Iglesias

Antón

Treatment of uveitis associated with juvenile idiopathic arthritis. Curr Rheumatol Rep 2014; 16(8): 437.

Mintz-Hittner

Geloneck

Chuang

AZ.

Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology 2016; 123(9): 1845–1855.

Wong

Desai

Jain

et al . Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 2008; 28(8): 1151–1158.

Shields

Honavar

et al . Classification and management of Coats disease: the 2000 Proctor lecture. Am J Ophthalmol 2001; 131(5): 572–583.

Silodor

Augsburger

Shields

et al . Natural history and management of advanced Coats’ disease. Ophthalmic Surg 1988; 19(2): 89–93.

Han

Choung

Heo

et al . The effects of external subretinal fluid drainage on secondary glaucoma in Coats disease. J AAPOS 2006; 10(2): 155–158.

Yoshizumi

Kreiger

Lewis

et al . Vitrectomy techniques in late-stage Coats-like exudative retinal detachment. Doc Ophthalmol 1995; 90(4): 387–394.

10.

Schmidt-Erfurth

Lucke

Vitreoretinal surgery in advanced Coats disease. Ger J Ophthalmol 1995; 4: 32–36.

11.

Mrejen

Metge

Denion

et al . Management of retinal detachment in Coats disease. Retina 2008; 28(3 Suppl.): S26–S32.

12.

Sun

Jain

Moshfeghi

DM.

Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium. Graefes Arch Clin Exp Ophthalmol 2007; 245(9): 1387–1388.

13.

Wang

Zhao

et al . Elevated vascular endothelial growth factor level in Coats’ disease and possible therapeutic role of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2010; 248(10): 1519–1521.

14.

Zhang

Liu

ZL.

Increased nitric oxide and vascular endothelial growth factor levels in the aqueous humor of patients with Coats’ disease. J Ocul Pharmacol Ther 2012; 28(4): 397–401.

15.

Zhao

Peng

Chen

et al . Vascular endothelial growth factor in Coats’ disease. Acta Ophthalmol 2014; 92(3): e225–e228.

16.

Kase

Rao

Yoshikawa

et al . Expression of vascular endothelial growth factor in eyes with Coats’ disease. Invest Ophthalmol Vis Sci 2013; 54(1): 57–62.

17.

Zhao

Wang

et al . Resolution of total retinal detachment in Coats’ disease with intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol 2011; 249(11): 1745–1746.

18.

Entezari

Ramezani

Safavizadeh

et al . Resolution of macular edema in Coats’ disease with intravitreal bevacizumab. Indian J Ophthalmol. 2010; 58(1): 80–82.

19.

Venkatesh

Mandal

Garg

Management of Coats disease with bevacizumab in 2 patients. Can J Ophthalmol 2008; 43(2): 245–246.

20.

Zheng

Jiang

YR.

The effect of intravitreal bevacizumab injection as the initial treatment for Coats’ disease. Graefes Arch Clin Exp Ophthalmol 2014; 252(1): 35–42.

21.

Lin

Hwang

Chen

et al . The effect of intravitreal bevacizumab in the treatment of Coats disease in children. Retina 2010; 30(4): 617–622.

22.

Cackett

Wong

Cheung

CM.

Combined intravitreal bevacizumab and argon laser treatment for Coats’ disease. Acta Ophthalmol 2010; 88(2): e48–e49.

23.

Alvarez-Rivera

Abraham-Marin

Flores-Orta

et al . Coat’s disease treated with bevacizumab (Avastin). Arch Soc Esp Oftalmol 2008; 83(5): 329–331.

24.

Huang

Lai

WC.

Integrating scleral buckling, transscleral drainage of subretinal fluid, intravitreal anti-vascular endothelial growth factor, and laser photocoagulation in stage 3B Coats’ total retinal detachment. Ophthalmic Surg Lasers Imaging Retina 2016; 47(9): 865–868.

25.

Sein

Tzu

Murray

et al . Treatment of Coats’ disease with combination therapy of intravitreal bevacizumab, laser photocoagulation, and sub-tenon corticosteroids. Ophthalmic Surg Lasers Imaging Retina 2016; 47(5): 443–449.

26.

Villegas

Gold

Berrocal

et al . Advanced Coats’ disease treated with intravitreal bevacizumab combined with laser vascular ablation. Clin Ophthalmol 2014; 8: 973–976.

27.

Ramasubramanian

Shields

CL.

Bevacizumab for Coats’ disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol 2012; 96(3): 356–359.

28.

Kaul

Uparkar

Mody

et al . Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats’ disease in children. Indian J Ophthalmol 2010; 58(1): 76–78.

29.

Stanga

Jaberansari

Bindra

et al . Transcleral drainage of subretinal fluid, anti-vascular endothelial growth factor, and wide-field imaging-guided laser in coats exudative retinal detachment. Retina 2016; 36(1): 156–162.

30.

Stergiou

Symeonidis

Dimitrakos

SA.

Coats’ disease: treatment with intravitreal bevacizumab and laser photocoagulation. Acta Ophthalmol 2009; 87(6): 687–688.

31.

Kodama

Sugioka

Kusaka

et al . Combined treatment for Coats’ disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases. BMC Ophthalmol 2014; 14: 36.

32.

Ray

Baranano

Hubbard

GB.

Treatment of Coats’ disease with intravitreal bevacizumab. Br J Ophthalmol 2013; 97(3): 272–277.

33.

Cakir

Cekic

Yilmaz

OF.

Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease. J AAPOS 2008; 12(3): 309–311.

34.

Bohm

Uhlig

CE.

Use of intravitreal triamcinolone and bevacizumab in Coats’ disease with central macular edema. Graefes Arch Clin Exp Ophthalmol 2011; 249(7): 1099–1101.

35.

Scott

AW.

Ophthalmic manifestations of sickle cell disease. South Med J 2016; 109(9): 542–548.

36.

Pahl

Green

Bhatia

et al . New ways to detect pediatric sickle cell retinopathy: a comprehensive review. J Pediatr Hematol Oncol 2017; 39(8): 618–625.

37.

Myint

Sahoo

Moe

et al . Laser therapy for retinopathy in sickle cell disease. Cochrane Database Syst Rev 2013; 10: CD010790.

38.

Siqueira

Costa

Scott

et al . Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand 2006; 84(6): 834–835.

39.

Shaikh

Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy. Indian J Ophthalmol 2008; 56(3): 259.

40.

Babalola

OE.

Intravitreal bevacizumab (Avastin) associated with secondary hyphaema in a case of proliferative sickle cell retinopathy. BMJ Case Rep. Epub ahead of print 30 March 2010. DOI: 10.1136/bcr.11.2009.2441.

41.

Moshiri

et al . Bevacizumab presurgical treatment for proliferative sickle-cell retinopathy-related retinal detachment. Retin Cases Brief Rep 2013; 7(3): 204–205.

42.

Ranchod

Drenser

et al . Clinical presentation of familial exudative vitreoretinopathy. Ophthalmology 2011; 118(10): 2070–2075.

43.

Pendergast

Trese

MT.

Familial exudative vitreoretinopathy: results of surgical management. Ophthalmology 1998; 105(6): 1015–1023.

44.

Fei

Yang

Zhang

et al . Surgical management of advanced familial exudative vitreoretinopathy with complications. Retina 2016; 36(8): 1480–1485.

45.

VanRaay

Vetter

ML.

Wnt/frizzled signaling during vertebrate retinal development. Dev Neurosci 2004; 26(5–6): 352–358.

46.

Sivaprasad

Moore

AT.

Choroidal neovascularisation in children. Br J Ophthalmol 2008; 92(4): 451–454.

47.

Rishi

Gupta

Rishi

et al . Choroidal neovascularization in 36 eyes of children and adolescents. Eye 2013; 27(10): 1158–1168.

48.

Sundaram

Uparkar

Athale

et al . Intravitreal bevacizumab (Avastin) in a pediatric case of pathologic myopia. Retin Cases Brief Rep 2007; 1(4): 192–194.

49.

Salman

AG.

Intravitreal bevacizumab for pediatric exudative retinal diseases. Saudi J Ophthalmol 2011; 25(2): 193–197.

50.

Agarwal

Kantha

Mayor

et al . Bilateral choroidal osteoma with choroidal neovascular membrane treated with bevacizumab in a child. Middle East Afr J Ophthalmol 2014; 21(3): 265–267.

51.

Piermarocchi

Benetti

Fracasso

Intravitreal bevacizumab for posttraumatic choroidal neovascularization in a child. J AAPOS 2011; 15(3): 314–316.

52.

Rishi

Venkatraman

Intravitreal bevacizumab for treatment of choroidal neovascularization associated with osteogenesis imperfecta. Indian J Ophthalmol 2012; 60(3): 229–231.

53.

Belliveau

Xing

Almeida

et al . Peripapillary choroidal neovascular membrane in a teenage boy: presenting feature of idiopathic intracranial hypertension and resolution with intravitreal bevacizumab. J Neuroophthalmol 2013; 33(1): 48–50.

54.

Mathur

George

Sen

Paediatric choroidal neovascular membrane secondary to toxoplasmosis treated successfully with anti-vascular endothelial growth factor. Oman J Ophthalmol 2014; 7(3): 141–143.

55.

Kohly

Muni

Kertes

et al . Management of pediatric choroidal neovascular membranes with intravitreal anti-VEGF agents: a retrospective consecutive case series. Can J Ophthalmol 2011; 46(1): 46–50.

56.

Khan

DeCroos

Storey

et al . Outcomes of anti-vascular endothelial growth factor therapy in the management of choroidal neovascularization associated with choroidal osteoma. Retina 2014; 34(9): 1750–1756.

57.

Celea

Pop

Avidis-Zamfiroiu

et al . Evolution of choroidal neovascular membrane in best disease after single intravitreal bevacizumab. Maedica 2015; 10(1): 61–64.

58.

Hussain

Shahid

Empeslidis

et al . Use of intravitreal bevacizumab in a 9-year-old child with choroidal neovascularization associated with autosomal recessive bestrophinopathy. Ophthalmic Genet 2015; 36(3): 265–269.

59.

Latanza

Viscogliosi

Solimeo

et al . Choroidal neovascularisation as an unusual ophthalmic manifestation of cat-scratch disease in an 8-year-old girl. Int Ophthalmol 2015; 35(5): 709–716.

60.

Grewal

Tran-Viet

Vajzovic

et al . Association of pediatric choroidal neovascular membranes at the temporal edge of optic nerve and retinochoroidal coloboma. Am J Ophthalmol 2017; 174: 104–112.

61.

Kozak

Mansour

Diaz

et al . Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: the results of the KKESH International Collaborative Retina Study Group. Retina 2014; 34(10): 2044–2052.

62.

Nussenblatt

Kaufman

Palestine

et al . Macular thickening and visual acuity: measurement in patients with cystoid macular edema. Ophthalmology 1987; 94(9): 1134–1139.

63.

Golan

Loewenstein

Surgical treatment for macular edema. Semin Ophthalmol 2014; 29(4): 242–256.

64.

Gilbert

Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008; 84(2): 77–82.

65.

Heidary

Vanderveen

Smith

LE.

Retinopathy of prematurity: current concepts in molecular pathogenesis. Semin Ophthalmol 2009; 24(2): 77–81.

66.

Early Treatment of Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity. Arch Ophthalmol 2003; 121: 1684–1696.

67.

Dorta

Kychenthal

Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin). Retina 2010; 30(4 Suppl.): S24–S31.

68.

Sahin

Cingu

et al . Intravitreal bevacizumab monotherapy for retinopathy of prematurity. Pediatr Int 2013; 55(5): 599–603.

69.

Nicoara

Nascutzy

Cristian

et al . Outcomes and prognostic factors of intravitreal bevacizumab monotherapy in zone I stage 3+ and aggressive posterior retinopathy of prematurity. J Ophthalmol 2015; 2015: 102582.

70.

Larranaga-Fragoso

Peralta

Bravo-Ljubetic

et al . Intravitreal bevacizumab for zone II retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 2016; 53(6): 375–382.

71.

Zhang

Yang

Zeng

et al . Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina 2016; 37: 710–717.

72.

Wallace

Kraker

Freedman

et al . Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol 2017; 135(6): 654–656.

73.

Quinn

Dobson

Kivlin

et al . Prevalence of myopia between 3 months and 5½ years in preterm infants with and without retinopathy of prematurity. Ophthalmology 1998; 105(7): 1292–1300.

74.

Quinn

Dobson

Davitt

et al . Progression of myopia and high myopia in the early treatment for retinopathy of prematurity study: findings to 3 years of age. Ophthalmology 2008; 115(6): 1058–1064.e1.

75.

Geloneck

Chuang

Clark

et al . Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 2014; 132(11): 1327–1333.

76.

Mintz-Hittner

Geloneck

MM.

Review of effects of anti-VEGF treatment on refractive error. Eye Brain 2016; 8: 135–140.

77.

Harder

Schlichtenbrede

vonBaltz

et al . Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 2013; 155(6): 1119–1124.e1.

78.

Hwang

Hubbard

Hutchinson

et al . Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology 2015; 122(5): 1008–1015.

79.

Isaac

Mireskandari

Tehrani

Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. J AAPOS 2015; 19(2): 140–144.

80.

Wang

Xiang

Early clinical characteristics of bacterial endophthalmitis in retinopathy of prematurity after intravitreal bevacizumab injection: a case report. Exp Ther Med 2017; 13(6): 3563–3566.

81.

Lepore

Quinn

Molle

et al . Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 2014; 121(11): 2212–2219.

82.

Yeh

Chen

et al . Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology 2011; 118(1): 176–183.

83.

Snyder

Garcia-Gonzalez

Shapiro

et al . Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging Retina 2016; 47(3): 280–283.

84.

Sato

Wada

Arahori

et al . Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012; 153(2): 327–333.e1.

85.

Lien

Hsu

et al . Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS ONE 2016; 11(1): e0148019.

86.

Morin

Luu

Superstein

et al . Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 2016; 137(4): e20153218.

87.

Sankar

Mehta

et al . Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev 2016; 2: CD009734.